We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA has accepted KV Pharmaceutical’s work plan to correct noncompliance with good manufacturing practices (GMPs), bringing the company one step closer to resuming product shipments.